These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

879 related items for PubMed ID: 25820920

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S, Ebadi M, Ghazizadeh F, Arzanian MT, Shamsian B, Abdollah Gorji F.
    Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
    [Abstract] [Full Text] [Related]

  • 3. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [Abstract] [Full Text] [Related]

  • 5. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M, Carrara P, Pinto V, Forni GL.
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract] [Full Text] [Related]

  • 6. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 7. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
    Gao HY, Li Q, Chen JJ, Chen GF, Li CG.
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul; 13(7):531-4. PubMed ID: 21752315
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN, El Rassi F, Taher AT.
    Expert Rev Hematol; 2016 Jul; 9(2):151-68. PubMed ID: 26613264
    [Abstract] [Full Text] [Related]

  • 10. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, Ng IO, Chan GC.
    Hemoglobin; 2006 Jul; 30(2):263-74. PubMed ID: 16798652
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA, Hamam MA, Taha OA, Hazaa SM.
    Infect Disord Drug Targets; 2015 Jul; 15(2):98-105. PubMed ID: 26205801
    [Abstract] [Full Text] [Related]

  • 13. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
    Vlachaki E, Agapidou A, Spanos G, Klonizakis P, Vetsiou E, Mavroudi M, Boura P.
    Hemoglobin; 2015 Jul; 39(5):299-304. PubMed ID: 26177199
    [Abstract] [Full Text] [Related]

  • 14. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM, Bassler D, Meerpohl JJ.
    Cochrane Database Syst Rev; 2017 Aug 15; 8(8):CD007476. PubMed ID: 28809446
    [Abstract] [Full Text] [Related]

  • 15. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, Tanphaichitr VS, Viprakasit V.
    Hemoglobin; 2014 Aug 15; 38(5):345-50. PubMed ID: 25051423
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
    Karimi M, Arandi N, Haghpanah S, Ansari S, Azarkeyvan A, Bordbar M, Safaei S.
    Hemoglobin; 2015 Aug 15; 39(5):327-9. PubMed ID: 26114738
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.
    Merchant R, Ahmed J, Krishnan P, Jankharia B.
    Indian Pediatr; 2012 Apr 15; 49(4):281-5. PubMed ID: 21992861
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.
    Chandra J, Chaudhary H, Pemde H, Singh V, Dutta AK.
    Ann Trop Paediatr; 2011 Apr 15; 31(1):47-51. PubMed ID: 21262109
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With β-Thalassemia Major: An Experience From North India.
    Parakh N, Chandra J, Sharma S, Dhingra B, Jain R, Mahto D.
    J Pediatr Hematol Oncol; 2017 Apr 15; 39(3):209-213. PubMed ID: 28221264
    [Abstract] [Full Text] [Related]

  • 20. Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
    Efthimia V, Neokleous N, Agapidou A, Economou M, Vetsiou E, Teli A, Perifanis V.
    Ann Hematol; 2013 Jan 15; 92(2):263-5. PubMed ID: 22933235
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.